Patenting and Pricing Eliquis, Ozempic, and Other Medicare-Targeted Drugs
Update: 2025-07-29
Description
Teddy Downey, Executive Editor of The Capitol Forum, sits down with Tahir Amin, co-founder of I-MAK, to discuss the pharmaceutical industry’s misuse of the U.S. patent system—and what it costs American patients and taxpayers.
They dive into I-MAK’s new report, Overpatented, Overpriced, and explore:
- How drugs like Eliquis and Ozempic are protected by dozens to hundreds of patents
- The role of patent term extensions, follow-on patents, and settlement deals in delaying generic competition
- How companies like Novo Nordisk and BMS generate tens of billions in additional revenue through strategic patenting
- Why the Hatch-Waxman Act and USPTO are failing to protect patients and the public interest
Full report: https://www.i-mak.org/overpatented/
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
